HK1206600A1 - Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3 - Google Patents

Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3

Info

Publication number
HK1206600A1
HK1206600A1 HK15107093.4A HK15107093A HK1206600A1 HK 1206600 A1 HK1206600 A1 HK 1206600A1 HK 15107093 A HK15107093 A HK 15107093A HK 1206600 A1 HK1206600 A1 HK 1206600A1
Authority
HK
Hong Kong
Prior art keywords
dihydroxyvitamin
methylene
secondary hyperparathyroidism
treat secondary
treat
Prior art date
Application number
HK15107093.4A
Other languages
English (en)
Chinese (zh)
Inventor
Hector F Deluca
Lori A Plum
Julia B Zella
Margaret Clagett-Dame
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206600(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of HK1206600A1 publication Critical patent/HK1206600A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15107093.4A 2012-06-29 2015-07-24 Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3 HK1206600A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (1)

Publication Number Publication Date
HK1206600A1 true HK1206600A1 (en) 2016-01-15

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107093.4A HK1206600A1 (en) 2012-06-29 2015-07-24 Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3

Country Status (19)

Country Link
US (4) US9205096B2 (es)
EP (1) EP2866811A1 (es)
JP (1) JP2015522015A (es)
KR (1) KR20150030673A (es)
CN (1) CN104394871A (es)
AU (1) AU2013281217B2 (es)
BR (1) BR112014032847A2 (es)
CA (1) CA2877680C (es)
CL (1) CL2014003565A1 (es)
CO (1) CO7240358A2 (es)
HK (1) HK1206600A1 (es)
IL (1) IL236184A0 (es)
MX (1) MX2015000076A (es)
MY (1) MY172886A (es)
NZ (1) NZ703347A (es)
RU (1) RU2666995C2 (es)
SG (1) SG11201408731WA (es)
WO (1) WO2014003849A1 (es)
ZA (1) ZA201500119B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015000076A (es) * 2012-06-29 2015-04-10 Wisconsin Alumni Reasearch Foundation Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
AU2014324669B2 (en) 2013-09-27 2020-06-04 Codexis, Inc. Automated screening of enzyme variants
NZ717647A (en) * 2013-09-27 2020-06-26 Codexis Inc Structure based predictive modeling
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
CN114681468A (zh) * 2014-08-07 2022-07-01 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d的辅助疗法
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
WO2018044468A1 (en) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
EP1267886B1 (en) 2000-03-27 2006-03-08 Wisconsin Alumni Research Foundation Vitamin d compounds for the treatment of chronic allograft nephropathy in kidney transplant patients
EP1301189A2 (en) * 2000-07-14 2003-04-16 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D 3? TO INCREASE BONE STRENGTH
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
WO2005027914A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
AU2006213727B2 (en) 2005-02-11 2011-08-18 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
AU2010281391B2 (en) * 2009-08-03 2015-05-07 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
WO2011119610A2 (en) 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
MX2015000076A (es) * 2012-06-29 2015-04-10 Wisconsin Alumni Reasearch Foundation Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.

Also Published As

Publication number Publication date
US9205096B2 (en) 2015-12-08
CA2877680C (en) 2017-08-29
RU2666995C2 (ru) 2018-09-13
CO7240358A2 (es) 2015-04-17
MY172886A (en) 2019-12-13
US20160136184A1 (en) 2016-05-19
US20140187522A1 (en) 2014-07-03
WO2014003849A1 (en) 2014-01-03
KR20150030673A (ko) 2015-03-20
CN104394871A (zh) 2015-03-04
ZA201500119B (en) 2017-11-29
US10046000B2 (en) 2018-08-14
NZ703347A (en) 2016-05-27
IL236184A0 (en) 2015-01-29
US20170252360A1 (en) 2017-09-07
CA2877680A1 (en) 2014-01-03
AU2013281217A1 (en) 2015-01-22
US9034853B2 (en) 2015-05-19
EP2866811A1 (en) 2015-05-06
AU2013281217B2 (en) 2017-03-02
JP2015522015A (ja) 2015-08-03
CL2014003565A1 (es) 2015-08-28
SG11201408731WA (en) 2015-01-29
US9717744B2 (en) 2017-08-01
BR112014032847A2 (pt) 2017-06-27
RU2015102831A (ru) 2016-08-20
MX2015000076A (es) 2015-04-10
US20140005152A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
HK1206600A1 (en) Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3
ZA201501730B (en) Pyrolytic reactor
HK1214473A1 (zh) 緊急牽引繩
ZA201307367B (en) Method of securing non-native code
ZA201406073B (en) Tetramerisation of ethylene
EP2924147A4 (en) PHOTOCHEMICAL REACTION SYSTEM
EP2812777A4 (en) STRING COMPLETION
GB201201566D0 (en) New chemical compounds
ZA201406074B (en) Tetramerisation of ethylene
ZA201503155B (en) Post-treatment of deboronated mww zeolite
IL229520B (en) Water treatment, especially for obtaining highly purified water
IL237483A0 (en) Preparations for the treatment of psoriasis
EP2937219A4 (en) PRINTER MASSICOT
PL2931842T3 (pl) Przekształcanie olejów zawierających triacyloglicerydy
EP2884975A4 (en) METHOD OF TREATING ONYCHOMYCOSIS
GB201309274D0 (en) Treatment Of Fuel
GB201222683D0 (en) Chemical reactor
HUE044624T2 (hu) Huminsav preparátum alkalmazása melegvérû állatok kezelésére
EP3240549A4 (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
EP2881717A4 (en) STRUCTURE FOR MASKS
PL2859647T3 (pl) Ruchoma platforma produkcji elektryczności w trybie awaryjnym lub jako skrajnej końcówki
EP2852411A4 (en) ANTI-CCL2 ANTIBODIES FOR THE TREATMENT OF SCLEROMERMIA
GB2515701B (en) Safety scalpel
GB201220869D0 (en) Process for sysnthesis of C2-substitutes analogues of 1a,25-dihydroxyvitamin D3
HK1168242A2 (en) Chemical tank